

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Nitroso-Redox Crosstalk in Diabetic Cardiomyopathy

Daniel R González, Adriana V Treuer and
Ulises Novoa

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/63668>

Abstract

Diabetes mellitus is one of the most common chronic diseases worldwide. Diabetic cardiomyopathy (DM) is the deterioration of the myocardial function and morphology produced by the altered glucose metabolism imposed in diabetes. This process of cardiac deterioration involves the generation of oxidative species. In the diabetic heart, several sources contribute to the observed oxidative stress, such as xanthine oxidoreductase (XOR), nicotinamide adenine dinucleotide phosphate (NADPH), nitrogen oxidases (NOX), mitochondria, and uncoupled nitric oxide synthases (NOS). A direct consequence of the increased production of reactive oxygen species (ROS) is NOS uncoupling. This is the aftermath of the oxidation of tetrahydrobiopterin (BH4), an essential cofactor for NOS activity. When NOS is uncoupled, its activity is redirected toward the production of superoxide, instead of nitric oxide (NO), further contributing to the oxidative process. This nitroso-redox disarrangement has a direct impact on the excitation-contraction-coupling machinery of the myocyte, in the mitochondrial stability impairing energy production and favoring apoptosis, myocardial fibrosis, ultimately reducing cardiac function. This review focuses on the impact of superoxide sources in the diabetic heart and the pharmacological approaches that are currently under investigation as possible therapeutic tools.

Keywords: Superoxide, nitric oxide, BH4, NOX, XOR

1. Introduction

Diabetes mellitus is one of the most common chronic diseases worldwide [1] and continues to increase in numbers and significance, with characteristics of an epidemic [2], as modern lifestyles lead to reduced physical activity and increased obesity.

Diabetic cardiomyopathy is the manifestation in the myocardium of the alterations produced by the altered homeostasis of glucose metabolism [3], independent of coronary artery disease and hypertension. This cardiomyopathy is characterized initially by diastolic dysfunction and cardiac hypertrophy, with preserved ejection fraction [4]. As diabetes progress, systolic dysfunction and reduced ejection fraction are developed [5]. This process of cardiac deterioration in diabetes includes oxidative stress [6] that results in apoptosis [7–9] and fibrosis that further deteriorate the myocardium. Despite the importance of diabetic cardiomyopathy as a clinical entity, the pathological cellular and molecular mechanisms driving the adverse changes in diabetic myocardial structure and function have not been fully resolved, but the development and progression of diabetic complications is frequently attributed to increased oxidative stress [6].

Reactive oxygen species (ROS) consist of a variety of highly reactive oxygen-based molecules that consist of both free radicals and chemicals capable of generating free radicals, such as superoxide, H_2O_2 , and peroxynitrite (ONOO^-) [10]. Although in health the primary source of ROS is the mitochondria [11], they are also produced by a range of other sources such as xanthine oxidase, NADPH oxidases and uncoupled nitric oxide synthase (NOS). Oxidative stress takes place when the rate of production of ROS overrides the degradation by antioxidant enzymes. An increase in ROS levels leads to a constellation of harmful consequences by producing damage by oxidative modifications, diminishing of nitric oxide (NO) bioavailability, and by inducing alteration in the intracellular-signaling pathways [12]. In a variety of studies in animal models of diabetes and humans with diabetic cardiomyopathy, it has been shown that increased ROS levels [11, 13] have been associated with the pathophysiology of heart failure, including from cardiac remodeling and mechanical impairment [14]. This ROS-induced damage is probably a consequence of oxidative damage to cardiac proteins and also by inducing cell death in the myocardium [8, 13, 15].

In diabetes, the resultant hyperglycemia, hyperlipidemia, and insulin resistance enhance oxidative stress in the diabetic heart [16]. Altered glucose flux, mitochondrial dysfunction, and nitric oxide synthase uncoupling jeopardize the diabetic myocardium, increasing the risk of cardiac remodeling and the transition toward heart failure [3].

In the diabetic heart, the alterations in the excitation-contraction coupling machinery are profound [17]. The levels of the sarcoendoplasmic reticulum Ca^{2+} pump (SERCA) are reduced [18], and total phospholamban (PLB) is increased [19], while phosphorylated phospholamban is reduced. Phospholamban is a 5 kDa protein that tonically inhibits the activity of SERCA2. Upon activation, phospholamban is phosphorylated (by PKA or CamKII, for instance), oligomerizes, and releases SERCA of its inhibition [20]. In this condition, Ca^{2+} is transported back into the sarcoplasmic reticulum at a higher rate. The expression of the calcium release channel ryanodine receptor (RyR2) and the sodium-calcium exchanger (NCX) are reduced in general [18, 19, 21–24]. Functionally, this pattern of protein expression is associated with impaired relaxation, increased sarcoplasmic reticulum calcium leak, and reduced contractility.

Altered calcium handling has been characterized in the diabetic cardiac myocytes [17]. Reduced capacity of the sarcoplasmic reticulum Ca^{2+} pump SERCA2 results in a diminished storage capacity of Ca^{2+} that impairs cardiac contractility [18, 19, 25]. Importantly, it also alters cardiac relaxation, which is evidenced in the diastolic dysfunction.

Oxidative stress may affect Ca^{2+} handling in the heart, at the level of the ryanodine receptor (RyR2) [26–28], which is the Ca^{2+} release channel of the sarcoplasmic reticulum. This channel is particularly redox sensitive and has been described that oxidative modification alters its function, leading to diastolic leak of Ca^{2+} , with a negative impact of contractility and relaxation [28–30].

In diabetes, several sources may contribute to the observed oxidative stress, such as xanthine oxidoreductase (XOR) [31, 32], NADPH oxidases (NOX) [33–35], mitochondria [11], and uncoupled nitric oxide synthases (NOS) [36, 37]. Apparently, the main source of superoxide in the diabetic heart corresponds to XOR and NOX. These latter enzymes are present in the heart, mainly with the isoforms NOX2 and NOX4.

A direct consequence of the increased production of ROS is the uncoupling of nitric oxide synthase [38]. This is due to the oxidation of tetrahydrobiopterin, an essential cofactor for NOS activity [39]. When NOS is uncoupled, its activity is redirected toward the production of superoxide, instead of NO [26], further contributing to the oxidative process.

2. NADPH oxidases NOX

Nicotinamide adenine dinucleotide phosphate oxidase enzymes (NADPH oxidases or NOX) received growing attention as a source of ROS and particularly for their involvement in redox signaling [40]. NOX exist in several isoforms (NOX1, 2, 4, and 5) [41]. These enzymes catalyze for electron transfer from NADPH to molecular oxygen, resulting in the generation of oxygen-free radicals. NADPH oxidase is increased in both failing and diabetic rodent hearts [42–44]. In diabetic rodents, the upregulation of NADPH oxidase correlates with morphological evidence of cardiac hypertrophy and upregulation of pro-fibrotic genes [42, 43, 45].

NOX2 is formed by the membrane-associated $\text{p}22^{\text{phox}}$ and one $\text{gp}91^{\text{phox}}$. The translocation of the cytosolic regulatory subunits $\text{p}40^{\text{phox}}$, $\text{p}47^{\text{phox}}$, $\text{p}67^{\text{phox}}$ and the small G protein Rac1 (the isoform expressed in the cardiomyocyte) or Rac2 is necessary for the occurrence of electron transfer from NADPH to oxygen. Under stimulation, for instance, with high levels of glucose or AngII, PKC is activated, leading to phosphorylation of $\text{p}47^{\text{phox}}$, an event that promotes the association of cytosolic subunits with $\text{p}22^{\text{phox}}$ and $\text{gp}91^{\text{phox}}$ [41] (**Figure 1**). In the cardiovascular system, these enzymatic components are expressed in endothelial cells, smooth muscle, cardiomyocytes, and fibroblasts [41, 46].




Figure 1. Mechanism of NADPH oxidase activation. Upon proper stimulus, Rac is activated and p47^{phox} is phosphorylated. Then p47^{phox} binds p40^{phox} and p67^{phox} and along with Rac, translocate to the cell membrane, where they activate NOX2 superoxide production.

2.1. NOX in diabetes

Several reports indicate that an increased activity of NOX, particularly NOX2 [34, 43, 47, 48] and NOX4 [35], may be implicated in the pathophysiology of diabetic cardiomyopathy. Hyperglycemia induces O₂⁻ generation in the heart primarily by disruption of the electron transport chain in mitochondria, activation of NOX and uncoupling of NOS. In type-2 diabetes, a state of permanent oxidative stress alters mitochondrial function, impairing energy production and ultimately producing cardiomyocyte dysfunction. Elevated glucose levels have been shown to stimulate NOX activity, increasing NOX-derived superoxide production in cardiac cells [48].

2.2. Physiological functions of NOX2

Recently, Prosser *et al.* elegantly demonstrated a physiological role for NOX2 in the cardiac myocytes, demonstrating that NOX2 activity is required to stimulate RyR2 in conditions of physiological stretching (preload). NOX2 activation upon stretching sensitizes RyR2 increasing the rate of Ca²⁺ sparks [49]. This mechanism becomes dysregulated in dystrophic cardiomyopathy [50]. Furthermore, more recently, it has been published that NOX2 in conjunction with NOS1 are absolutely required for another cardiac physiological response to an increase in afterload (Anrep effect) [51]. NOX2 oxidase has been implicated in the cardiac dysfunction observed in ob/ob cardiac myocytes [34, 52].

2.3. NOX2 and diabetic cardiomyopathy

Several lines of evidence showed a role of NOX2 in the diabetic cardiomyopathy [53, 54]. First, NOX2 is activated and its subunits are upregulated in several models of diabetes and insulin resistance, streptozotocin-treated mice, ob/ob and db/db mice, and fructose-fed rats, with increased oxidative stress as a consequence.

Using streptozotocin-treated mice, Roe *et al.* [55] described that pharmacological inhibition of NADPH oxidase with apocynin reduced part of the cardiac damage and it improved heart functional evaluated as fractional shortening, and cardiomyocytes mechanics, associated with a reduction in nitrosative and oxidative stress. Nevertheless, since apocynin is not a specific inhibitor for NOX2, these results might be ascribed also to NOX4, which is also present in the cardiomyocyte.

Evidence for a more specific and crucial role for NOX2 came from studies using knock out for Rac1, one of the cytosolic components of the holoenzyme complex. In cardiac-specific Rac-1 knockout mice, induction of diabetes by streptozotocin treatment showed reduced apoptosis, fibrosis and improved cardiac function compared to wild-type animals [56, 57]. The mechanisms of reduced cardiac damage involves a reduction in NADPH oxidase activity, a reduction in mitochondrial ROS production that attenuates fetal gene program, reduces the inflammatory process, and reduces endoplasmic reticulum stress. In addition, cardiomyocyte-specific deletion of Rac-1 reduces cardiac damage in diabetic mice after ischemia-reperfusion by reducing calpain proteolytic activity [58].

2.4. NOX4

NOX4 is expressed constitutively in the heart and its activity has been ascribed as mitochondrial [59]. Its physiological role has not been clarified. On the contrary, there are descriptions of NOX4 in pathological conditions that are both beneficial [60] and deleterious [44]. Indeed, Sadoshima's group has shown that NOX4 is an important source of oxidative stress in a mouse model of pressure overload (by aortic constriction). In this study, NOX4 deletion was associated with preserved ejection fraction and reduced hypertrophy, apoptosis, and mitochondrial function compared to wild-type animals [44]. Nevertheless, these results are contrary to those observed by Shah's group. These investigators reported a protective role for NOX4, using the same strategy (pressure overload in a cardiomyocyte-specific knock-out mouse for NOX4), with the difference that they additionally used a mouse with cardiomyocyte-targeted increase in NOX4, which showed an increased angiogenesis in response to overload [60].

Regarding diabetic cardiomyopathy, Maalouf *et al.* reported that NOX4 plays a pivotal role in the cardiac damage in streptozotocin-treated rats. They found that NOX4 was up upregulated and when silenced using antisense oligonucleotides, this was reversed, along with the induction of fetal program genes and fibrosis, as well as cardiac function [35].

3. Xanthine oxidoreductase

Xanthine oxidoreductase (XOR) is a highly conserved member of the molybdoenzyme family. It consists of a 150 kDa homodimer that is involved in the purine degradation pathway, producing superoxide as a secondary metabolite. This precursor may further divert in the formation of two enzymatic activities, xanthine dehydrogenase (XDH) and xanthine oxidase (XO). XO is derived from XDH as a result of proteolysis or reversible oxidation of cysteines of XDH. Whereas XDH reduces NAD^+ to NADH, XO utilizes molecular oxygen as electron acceptor. They differ in that XO only reduces oxygen, whereas XDH can reduce either O_2 or NAD^+ . Both forms catalyze the conversion of hypoxanthine to xanthine and xanthine to uric acid. In both steps, O_2^- and H_2O_2 are produced [61]. Normally, in the cardiac myocyte, XOR is located in the sarcoplasmic reticulum, where it regulates some features of calcium handling and also myofilament calcium sensitivity. We have reported that XOR is upregulated in dilated cardiomyopathy, producing oxidative stress that interferes with NO signaling, resulting in dysregulated RyR2 activity, ultimately producing diastolic calcium leak and reducing contractility [28]. It is probably that in diabetes, XOR may impact negatively calcium handling, but this has not been clarified.

XOR has been implicated in the pathophysiology of streptozotocin-induced diabetic cardiomyopathy and its inhibition with allopurinol, oxypurinol, and antioxidants yielded some positive results that included improvement in cardiac function, reduction in oxidative stress, reduced cardiac apoptosis, fibrosis (collagen I), and hypertrophy [31, 33, 62]. In obese (ob/ob mice), XOR is upregulated and its activity increased, leading to alterations in the redox state of the heart, such as diminished GSH/GSSG ratio and decreased levels of NO metabolites [32].

Importantly, XOR has been shown to be increased in type-1 diabetic patients [63]. In addition, in a study in patients with type-2 diabetes and left ventricular hypertrophy, the treatment with allopurinol reduced left ventricular mass modestly but significantly in a period of 9 months of treatment, in a dosage that reduced plasma uric acid by ~50% [64].

4. Mitochondria

Due to their high-energy demand, cardiomyocytes are abundant in mitochondria. However, mitochondria are also an important source of ROS and NO [65, 66].

In physiological conditions, most of the reducing equivalents of the electron transport chain are directed toward the production of ATP and about 0.1% leak and produces superoxide [11].

Diabetes induces a series of metabolic derangements in myocardial mitochondria [12]. Under conditions of hyperglycemia, the mitochondrial inner membrane hyperpolarizes and inhibits the electron transport in complex III, generating superoxide [67].

Myocardial diabetic damage is reduced by overexpression of Mn SOD and catalase [57, 68] and by pharmacological inhibition of mitochondrial ROS by a mitochondrial-directed SOD

mimetic, mito-Tempo [69]. Noteworthy, besides being a source of ROS, mitochondria may suffer the consequences of increase oxidative stress as well [70]. High levels of ROS may sensitize the mitochondrial permeability transition pore (mPTP), releasing cytochrome C, and Smac/DIABLO ultimately inducing apoptosis [71]. The mitochondrial permeability transition pore is constituted by the adenine nucleotide translocase (ANT), the voltage-dependent anionic channel (VDAC), and cyclophilin D, which under stress conditions such as high Ca^{2+} or increased ROS make the mitochondrial membrane permeable to ions and molecules <1500 Da, dissipating the mitochondrial membrane potential [72]. In human atrial tissue from patients with diabetes, Anderson *et al.* [73] found increased H_2O_2 production, with increased sensitivity to Ca^{2+} -induced mPTP opening compared with nondiabetic patients and also in the heart of Zucker rats [74].

The components of the mPTP contain several redox-sensitive sites that can be oxidized or S-nitrosylated [71, 72]. S-Nitrosylation generally prevents mPTP opening, while oxidation sensitizes to opening (**Figure 2**). This is consistent with the fact that NO donors, at low concentrations, protect the mPTP from opening [72, 75, 76]. For instance, cyclophilin D has been shown to undergo S-nitrosylation in cysteine 203, preventing the oxidative-induced opening of the pore [77]. High NO donor concentrations, on the other, promote mPTP opening, associated with oxidation rather than hypernitrosylation. Nevertheless, the role of S-nitrosylation of mPTP in conditions of diabetic cardiomyopathy remains to be determined.




Figure 2. Potential role for nitric oxide in the mitochondrial permeability transition pore (PT). Nitric oxide produced within the mitochondria, probably by a mtNOS, reacts with sulfhydryl groups in the pore, S-nitrosylating them and preventing oxidation by ROS. This prevents the pore from opening and dissipating mitochondrial protons gradient.

In addition, mitochondria appear to play a central role in diabetic cardiomyopathy through alterations in the process of autophagy, and this process is clearly influenced by the mitochondrial oxidative status [15, 78–81].

5. Nitric oxide

Nitric oxide (NO) is a free radical that is produced by a family of NO synthases (NOSs), using NADPH, the amino acid L-arginine and oxygen as substrates. NOSs are homodimers and each subunit contains one flavin mononucleotide (FMN), one flavin adenine dinucleotide, one tetrahydrobiopterin (BH₄), and one Fe(3)-heme cofactor that facilitates the 5-electron oxidation of L-arginine to yield NO. In biological systems, NO exerts its effects by redox reactions (such as S-nitrosylation) or by inducing the production of cGMP as a second messenger [27, 82, 83].

Nitric oxide plays several important roles in the physiology of the myocardium, both in cardiomyocytes and in blood vessels [83–85]. NOS1 (former neuronal NOS) and eNOS (or NOS3) are expressed constitutively in the heart structures, particularly in the cardiomyocyte. NOS1 participates in the regulation of contractility [86, 87] by regulating RyR2 S-nitrosylation [29, 30] and phospholamban phosphorylation [88, 89]. NOS1 regulates the β -adrenergic [86, 90] and force-frequency response [29, 91] in the heart. Also NOS1 prevents cardiac dysfunction after a myocardial infarction and pressure overload [92–95]. For these reasons, the role for NO in diabetic cardiomyopathy has gained attention [96–98].

5.1. NOS1

Our group has recently identified specific stimulatory influences of NOS1 on both β -adrenergic inotropic responses and Ca²⁺ transients ([Ca²⁺]_i) using NOS1^{-/-} mice. These results are consistent with *in vitro* studies indicating that NO regulates SR Ca²⁺ release via the RyR by S-nitrosylation of a specific thiol moiety. RyR2 activation via nitrosylation is highly sensitive to ROS. We demonstrated non-cGMP related, redox-sensitive positive inotropic effects in isolated heart preparations [82] and demonstrated the role of NOS1 specifically in SR Ca²⁺ cycling [29, 99]. The interplay between NO and ROS is also of critical importance for Ca²⁺ handling. In the SR, NO augments RyR activity via S-nitrosylation in a manner regulated by ROS [100, 101]. ROS also activates the RyR2 but promotes maximal channel activity in an irreversible manner, reducing the ability of NO to exert feedback regulation of SR Ca²⁺ release. Such a situation is likely to lead to an increased Ca²⁺ leak through the SR and “futile” Ca²⁺ cycling, which increases ATP expenditure. It is also conceivable that oxidant signaling may directly regulate cross-bridge cycling kinetics, thereby modulating the efficiency of contraction.

5.2. NOS1 and cardioprotection

It has been consistently documented that NOS1 exerts a protective role in the myocardium in several models of stress, such as myocardial infarction [92, 93, 95], pressure overload [94, 102], ischemia-reperfusion [103], and dystrophic cardiomyopathy [104], just to mention the most relevant. Mechanistically, NOS1 nitrosylates several proteins, including ion channels [27, 29, 105] and mitochondrial components [106], and reduces oxidative stress [107].

A key hallmark of diabetic cardiomyopathy is hypertrophy. In this process, NO may play a role; furthermore, it has been shown that eNOS uncoupling (rather than the absence of NO) induces hypertrophy in the model of pressure overload [108]. Recoupling eNOS with BH₄

reverses this process, but not the use of tempol, a ROS scavenger [109, 110]. In ob/ob mice, myocardial hypertrophy has been documented [111], along with reduced NO bioavailability associated with reduced levels of NOS1 and increased NADPH [34] and XOR activity [32].

The activity of NOS1 is required for basal phospholamban phosphorylation in the mouse heart [88, 89], with NOS1 uncoupling resulting in an impaired ventricular relaxation and diastolic dysfunction, as observed in a model of hypertension [112]. Conversely, an increased production of BH₄ by cardiac-specific overexpression of GTP cyclohydrolase 1 (GCH1, the rate-limiting enzyme for BH₄ biosynthesis), accelerates myocardial relaxation [113]. NOS1 uncoupling in mdx cardiomyocytes is probably the result of the NOX2-derived oxidative stress, which ultimately leads to tetrahydrobiopterin oxidation. With this in mind, one possibility is that NOS1 is found in a monomeric form resulting in uncoupling. This uncoupling has been proposed as the aftermath of excessive tetrahydrobiopterin (BH₄), oxidation to dihydrobiopterin (BH₂).

5.3. NOS2

Inducible nitric oxide synthase (iNOS or NOS2) appears to play a central role in the pathophysiology of the diabetic cardiomyopathy [54]. In the heart, like in most tissues, iNOS is not constitutively expressed. Inflammatory conditions trigger the activation of the nuclear factor kappa beta (NF-κB). The activity of iNOS has been usually ascribed as part of the nitrosative stress. Since iNOS activity is much higher than the constitutive isoforms (NOS1 and 3), it reacts with superoxide, producing peroxynitrite [83]. This oxidant reacts with the aromatic ring of tyrosine residues, generating nitrotyrosine, one of the most widespread markers of nitrosative and oxidative stress [114]. iNOS-derived NO depresses cardiac contractility and function [115], and has been described to be upregulated in patients with diabetic cardiomyopathy [116].

iNOS expression has been manipulated pharmacologically in diabetes, using resveratrol, a natural polyphenol present in red wine and grapes. Resveratrol reduces the oxidative stress, improves myocardial relaxation [117] and reduces iNOS expression in type-2 diabetes models, by reducing the activation of NF-κB [118].

5.4. NOS uncoupling

In physiological conditions, NOS catalyze the reaction of oxidation of L-arginine to produce NO and L-citrulline, in the presence of NADPH, oxygen, and the cofactor 6R-5,6,7,8-tetrahydrobiopterin (BH₄). In the absence of BH₄, electrons coming from NADPH flow to molecular oxygen, but uncoupled of L-arginine, producing superoxide instead of NO [26]. Apparently, BH₄ stabilizes the NOS configuration as a dimer that favors the proper flow of electrons to L-arginine. In its absence, NOS monomerizes and only maintains its oxidase activity [119]. BH₄ and BH₂ have been shown to bind to NOS with similar affinity (K_d ~80 nM). Tetrahydrobiopterin essential cofactor for aromatic amino acid hydroxylases and NOS. BH₄ can be synthesized by two pathways: *de novo* or recycled from its oxidized forms (**Figure 3**). For *de novo* synthesis, GTP cyclohydrolase I (GTPCH), 6-pyruvoyl tetrahydrobiopterin synthase (PTPS), and sepiapterin reductase (SR) convert GTP to BH₄. In the first reaction catalyzed by GTPCH, guanosine

5'triphosphate (GTP) is reduced to 7,8-dihydroneopterin 3'triphosphate (DNTP), being the rate-limiting reaction. Next, the conversion of DNTP to 6-pyrovoyl tetrahydrobiopterin (PTP) is catalyzed by PTPS. The final reactions are two successive propyl side-chain reductions catalyzed by SR [39, 120].




Figure 3. NOS uncoupling in the cardiomyocyte. Upon increased oxidative stress, BH₄, which normally couples L-arginine and NADPH oxidation and NO production, oxidized to BH₂, which is unable to couple this reaction, with the NADPH electrons passing directly to oxygen, producing superoxide.

When BH₄ is oxidized to BH₂, is reduced back to BH₄ by the enzyme dihydrofolate reductase (DHFR), in the salvage pathway. It is worth mentioning that during NOS catalysis BH₄ is not consumed, indicating that BH₂ formation is probably the result of other oxidative processes such as oxidative stress [39, 120].

5.5. NOS uncoupling in diabetes

It has been reported that NOS uncoupling takes places in diabetes, particularly in the vasculature [121]. For this reason, it has been associated with NOS3 [36, 37], the NOS isoform that is dominant in the endothelium. Given that oxidative stress is increased and that cardiac relaxation is impaired in diabetes, it is reasonable to think that NOS1 is uncoupled in the diabetic cardiomyocyte, since this isoform is related to phospholamban phosphorylation. Interestingly, it has been reported in the gastrointestinal system that diabetes produces NOS1 uncoupling, which is restored upon treatment with BH₄ [122] and sepiapterin, a BH₄ precursor [123].

The first report relating NOS uncoupling and diabetes was performed in cardiomyocytes exposed to high glucose concentration [124]. In these conditions, treatment with BH₄ restored the mechanic parameters in cardiomyocytes toward normal, an effect that could not be obtained using tetrahydroneopterin, which also shares ROS-scavenging properties as BH₄. Furthermore, the treatment of normal myocytes with the GTP cyclohydrolase I inhibitor 2,4-diamino-6-hydroxy-pyrimidine (DAHP) resembled the features of myocytes under hyperglycemic conditions.

The same group described that treatment of insulin-resistant mice with the BH₄ precursor folic acid was able to produce NOS recoupling. These effects were associated with improved cardiac function and reduction of sarcoplasmic reticulum calcium leak in isolated cardiomyocytes [125].

Furthermore, Jo *et al.* described that treatment of streptozotocin-induced diabetic mice with the BH₄ precursor sepiapterin was able to restore the intracardiac BH₄ levels and restored the BH₄/BH₂ ratio in diabetic mice. This treatment recoupled NOS in wild type, eNOS- and nNOS-deficient mice, but not in iNOS-deficient mice, suggesting that iNOS uncoupling was responsible for the oxidative stress observed in type-1 diabetic mice. Importantly, this treatment restored ventricular function except in iNOS mice [126]. Apparently, NOS uncoupling is related to the increased activity of NADPH oxidase in streptozotocin-induced diabetic mice [55]. Furthermore, a recent report describes that in db/db mice, a model of type-2 diabetes, the coadministration of sepiapterin and L-citrulline, a precursor of L-arginine restored cardiac function in diabetic hearts and improved their response after ischemia-reperfusion [127].

6. Conclusion

In the diabetic heart, an increased hyperglycemia induced the mitochondrial production of ROS, which favors apoptosis. Concomitantly, diabetes induces the activation of NOX that further impairs mitochondrial function. In addition, the diabetic state induces the expression of iNOS, which in conjunction with an increased ROS production leads to the generation of peroxynitrite, a highly oxidizing species. These elements create a feed-forward system that deteriorates cardiac function at several levels. Furthermore, increased ROS production may oxidize BH₄, producing NOS uncoupling, further aggravating the oxidative damage.

Despite the heavy burden that diabetes imposes to the heart, current therapeutic strategies do not specifically address diabetes-induced heart failure; therefore, novel pharmacological treatments might be of high relevance. Theoretically, a reduction in mitochondrial or NOX derived-oxidative stress in diabetic cardiomyopathy should be able to improve some of the features of diabetic cardiomyopathy. Nevertheless, indiscriminate NOX inhibition or ROS quenching may have detrimental effects if the protective role of NOX4 (as opposed as other NOXs) is disturbed, as it has been suggested in several stress conditions for the myocardium. On the other hand, inhibitors of mitochondrial ROS production are still in their infancy and have not been tested in humans. Therefore, pharmacological restoration of intracardiac BH₄ levels may offer a new therapeutic opportunity for diabetic cardiomyopathy, as they have been used in other pathologies, although the results have been somehow disappointing [128]. In addition, isoform-specific NOX inhibitors are needed as pharmacological tools against diabetic cardiomyopathy.

Acknowledgements

This work was supported in part by the grant 1150662 from Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt) Chile, and Programa de Investigación en Química y Bioquímica de Recursos Naturales, Universidad de Talca, Talca, Chile.

Author details

Daniel R González*, Adriana V Treuer and Ulises Novoa

*Address all correspondence to: dagonzalez@utalca.cl

Department of Biomedical Sciences, School of Health Sciences, University of Talca, Talca, Chile

References

- [1] Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87:4–14.
- [2] Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001;414:782–7.
- [3] Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G. Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. *World J Diabetes* 2013;4:177–89.
- [4] Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, et al. Diabetic cardiomyopathy. *Clin Sci (Lond)* 2009;116:741–60.
- [5] Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. *Heart Fail Rev* 2012;17:325–44.
- [6] Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart. *J Pathol* 2013;229:232–41.
- [7] Barouch LA, Gao D, Chen L, Miller KL, Xu W, Phan AC, et al. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. *Circ Res* 2006;98:119–24.
- [8] Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. *Circ Res* 2000;87:1123–32.
- [9] Rota M, LeCapitaine N, Hosoda T, Boni A, De AA, Padin-Iruegas ME, et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. *Circ Res* 2006;99:42–52.
- [10] Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. *J Clin Invest* 2005;115:500–8.
- [11] Bugger H, Abel ED. Mitochondria in the diabetic heart. *Cardiovasc Res* 2010;88:229–40.

- [12] Lorenzo O, Ramirez E, Picatoste B, Egido J, Tunon J. Alteration of energy substrates and ROS production in diabetic cardiomyopathy. *Mediators Inflamm* 2013;2013:461967.
- [13] Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, Matsuoka TA, et al. Involvement of oxidative stress in the pathogenesis of diabetes. *Antioxid Redox Signal* 2007;9:355–66.
- [14] Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM. NADPH oxidase and heart failure. *Curr Opin Pharmacol* 2006;6:148–53.
- [15] Ouyang C, You J, Xie Z. The interplay between autophagy and apoptosis in the diabetic heart. *J Mol Cell Cardiol* 2014;71:71–80.
- [16] Mandavia CH, Aroor AR, Demarco VG, Sowers JR. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. *Life Sci* 2013;92:601–8.
- [17] Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. *Curr Hypertens Rep* 2004;6:424–9.
- [18] Zhao SM, Wang YL, Guo CY, Chen JL, Wu YQ. Progressive decay of Ca²⁺ homeostasis in the development of diabetic cardiomyopathy. *Cardiovasc Diabetol* 2014;13:75.
- [19] Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, et al. Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. *Am J Physiol Heart Circ Physiol* 2002;283:H1398–408.
- [20] Mattiazzi A, Kranias EG. The role of CaMKII regulation of phospholamban activity in heart disease. *Front Pharmacol* 2014;5:5.
- [21] Lacombe VA, Viatchenko-Karpinski S, Terentyev D, Sridhar A, Emani S, Bonagura JD, et al. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. *Am J Physiol Regul Integr Comp Physiol* 2007;293:R1787–97.
- [22] Shao CH, Wehrens XH, Wyatt TA, Parbhu S, Rozanski GJ, Patel KP, et al. Exercise training during diabetes attenuates cardiac ryanodine receptor dysregulation. *J Appl Physiol (1985)* 2009;106:1280–92.
- [23] Stolen TO, Hoydal MA, Kemi OJ, Catalucci D, Ceci M, Aasum E, et al. Interval training normalizes cardiomyocyte function, diastolic Ca²⁺ control, and SR Ca²⁺ release synchronicity in a mouse model of diabetic cardiomyopathy. *Circ Res* 2009;105:527–36.
- [24] Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML. Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. *Diabetes* 2008;57:2158–66.
- [25] Vasanji Z, Dhalla NS, Netticadan T. Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart. *Mol Cell Biochem* 2004;261:245–9.
- [26] Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited

changes in NO vs. superoxide production by eNOS. *Am J Physiol Heart Circ Physiol* 2008;294:H1530–40.

- [27] Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM. S-Nitrosylation of cardiac ion channels. *J Cardiovasc Pharmacol* 2009;54:188–95.
- [28] Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. *J Biol Chem* 2010;285:28938–45.
- [29] Gonzalez DR, Beigi F, Treuer AV, Hare JM. Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes. *Proc Natl Acad Sci U S A* 2007;104:20612–7.
- [30] Wang H, Viatchenko-Karpinski S, Sun J, Gyorke I, Benkusky NA, Kohr MJ, et al. Regulation of myocyte contraction via neuronal nitric oxide synthase: role of ryanodine receptor S-nitrosylation. *J Physiol* 2010;588:2905–17.
- [31] Rajesh M, Mukhopadhyay P, Batkai S, Mukhopadhyay B, Patel V, Hasko G, et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. *J Cell Mol Med* 2009;13:2330–41.
- [32] Saraiva RM, Minhas KM, Zheng M, Pitz E, Treuer A, Gonzalez D, et al. Reduced neuronal nitric oxide synthase expression contributes to cardiac oxidative stress and nitroso-redox imbalance in ob/ob mice. *Nitric Oxide* 2007;16:331–8.
- [33] Gao X, Xu Y, Xu B, Liu Y, Cai J, Liu HM, et al. Allopurinol attenuates left ventricular dysfunction in rats with early stages of streptozotocin-induced diabetes. *Diabetes Metab Res Rev* 2012;28:409–17.
- [34] Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca²⁺-ATPase and myosin heavy chain isozyme switch. *Diabetologia* 2006;49:1434–46.
- [35] Maalouf RM, Eid AA, Gorin YC, Block K, Escobar GP, Bailey S, et al. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. *Am J Physiol Cell Physiol* 2012;302:C597–604.
- [36] Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. *Diabetologia* 2000;43:1435–8.
- [37] Katakam PV, Snipes JA, Steed MM, Busija DW. Insulin-induced generation of reactive oxygen species and uncoupling of nitric oxide synthase underlie the cerebrovascular insulin resistance in obese rats. *J Cereb Blood Flow Metab* 2012;32:792–804.

- [38] Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 2003;111:1201–9.
- [39] Tejero J, Stuehr D. Tetrahydrobiopterin in nitric oxide synthase. *IUBMB Life* 2013;65:358–65.
- [40] Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev* 2007;87:245–313.
- [41] Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, et al. NADPH oxidases in cardiovascular health and disease. *Antioxid Redox Signal* 2006;8:691–728.
- [42] Grieve DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC, et al. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. *J Am Coll Cardiol* 2006;47:817–26.
- [43] Huynh K, Kiriazis H, Du XJ, Love JE, Gray SP, Jandeleit-Dahm KA, et al. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. *Free Radic Biol Med* 2013;60:307–17.
- [44] Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. *Proc Natl Acad Sci U S A* 2010;107:15565–70.
- [45] Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol Ther* 2014;142:375–415.
- [46] Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. *Trends Pharmacol Sci* 2003;24:471–8.
- [47] Lei S, Liu Y, Liu H, Yu H, Wang H, Xia Z. Effects of N-acetylcysteine on nicotinamide dinucleotide phosphate oxidase activation and antioxidant status in heart, lung, liver and kidney in streptozotocin-induced diabetic rats. *Yonsei Med J* 2012;53:294–303.
- [48] Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah AM, et al. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. *Circulation* 2006;113:1235–43.
- [49] Prosser BL, Ward CW, Lederer WJ. X-ROS signaling: rapid mechano-chemo transduction in heart. *Science* 2011;333:1440–5.
- [50] Gonzalez DR, Treuer AV, Lamirault G, Mayo V, Cao Y, Dulce RA, et al. NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. *Am J Physiol Heart Circ Physiol* 2014;307:H710–H721.

- [51] Jian Z, Han H, Zhang T, Puglisi J, Izu LT, Shaw JA, et al. Mechanochemotransduction during cardiomyocyte contraction is mediated by localized nitric oxide signaling. *Sci Signal* 2014;7:ra27.
- [52] Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. *Hypertension* 2006;47:222–9.
- [53] Kowluru A, Kowluru RA. Phagocyte-like NADPH oxidase [Nox2] in cellular dysfunction in models of glucolipotoxicity and diabetes. *Biochem Pharmacol* 2014;88:275–83.
- [54] Soskic SS, Dobutovic BD, Sudar EM, Obradovic MM, Nikolic DM, Djordjevic JD, et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. *Open Cardiovasc Med J* 2011;5:153–63.
- [55] Roe ND, Thomas DP, Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. *Diabetes Obes Metab* 2011;13:465–73.
- [56] Li J, Zhu H, Shen E, Wan L, Arnold JM, Peng T. Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. *Diabetes* 2010;59:2033–42.
- [57] Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q, et al. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. *Diabetes* 2009;58:2386–95.
- [58] Shan L, Li J, Wei M, Ma J, Wan L, Zhu W, et al. Disruption of Rac1 signaling reduces ischemia-reperfusion injury in the diabetic heart by inhibiting calpain. *Free Radic Biol Med* 2010;49:1804–14.
- [59] Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. *Circ Res* 2010;106:1253–64.
- [60] Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. *Proc Natl Acad Sci U S A* 2010;107:18121–6.
- [61] Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. *J Physiol* 2004;555:589–606.
- [62] Kumar S, Prasad S, Sitasawad SL. Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats. *PLoS One* 2013;8:e67009.
- [63] Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. *Diabetes* 2002;51:1118–24.

- [64] Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. *J Am Coll Cardiol* 2013;62:2284–93.
- [65] Dedkova EN, Blatter LA. Characteristics and function of cardiac mitochondrial nitric oxide synthase. *J Physiol* 2009;587:851–72.
- [66] Gonzalez DR, Treuer AV, Dulce RA. Neuronal nitric oxide synthase in heart mitochondria: a matter of life or death. *J Physiol* 2009;587:2719–20.
- [67] Teshima Y, Takahashi N, Nishio S, Saito S, Kondo H, Fukui A, et al. Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase. *Circ J* 2014;78:300–6.
- [68] Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. *Diabetes* 2004;53:1336–43.
- [69] Ni R, Cao T, Xiong S, Ma J, Fan GC, Lacefield JC, et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. *Free Radic Biol Med* 2015;90:12–23.
- [70] Tocchetti CG, Caceres V, Stanley BA, Xie C, Shi S, Watson WH, et al. GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. *Diabetes* 2012;61:3094–105.
- [71] Mailloux RJ, Jin X, Willmore WG. Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. *Redox Biol* 2014;2:123–39.
- [72] Bernardi P, Di LF. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. *J Mol Cell Cardiol* 2015;78:100–6.
- [73] Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypson AP. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. *Am J Physiol Heart Circ Physiol* 2011;300:H118–24.
- [74] Riojas-Hernandez A, Bernal-Ramirez J, Rodriguez-Mier D, Morales-Marroquin FE, Dominguez-Barragan EM, Borja-Villa C, et al. Enhanced oxidative stress sensitizes the mitochondrial permeability transition pore to opening in heart from Zucker Fa/fa rats with type 2 diabetes. *Life Sci* 2015;141:32–43.
- [75] Leite AC, Oliveira HC, Utino FL, Garcia R, Alberici LC, Fernandes MP, et al. Mitochondria generated nitric oxide protects against permeability transition via formation of membrane protein S-nitrosothiols. *Biochim Biophys Acta* 2010;1797:1210–6.

- [76] Ohtani H, Katoh H, Tanaka T, Saotome M, Urushida T, Satoh H, et al. Effects of nitric oxide on mitochondrial permeability transition pore and thiol-mediated responses in cardiac myocytes. *Nitric Oxide* 2012;26:95–101.
- [77] Nguyen TT, Stevens MV, Kohr M, Steenbergen C, Sack MN, Murphy E. Cysteine 203 of cyclophilin D is critical for cyclophilin D activation of the mitochondrial permeability transition pore. *J Biol Chem* 2011;286:40184–92.
- [78] Sciarretta S, Zhai P, Shao D, Zablocki D, Nagarajan N, Terada LS, et al. Activation of NADPH oxidase 4 in the endoplasmic reticulum promotes cardiomyocyte autophagy and survival during energy stress through the protein kinase RNA-activated-like endoplasmic reticulum kinase/eukaryotic initiation factor 2alpha/activating transcription factor 4 pathway. *Circ Res* 2013;113:1253–64.
- [79] Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. *Biochim Biophys Acta* 2015;1852:232–42.
- [80] Sciarretta S, Volpe M, Sadoshima J. NOX4 regulates autophagy during energy deprivation. *Autophagy* 2014;10:699–701.
- [81] Wang B, Yang Q, Sun YY, Xing YF, Wang YB, Lu XT, et al. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. *J Cell Mol Med* 2014;18:1599–611.
- [82] Gonzalez DR, Fernandez IC, Ordenes PP, Treuer AV, Eller G, Boric MP. Differential role of S-nitrosylation and the NO-cGMP-PKG pathway in cardiac contractility. *Nitric Oxide* 2008;18:157–67.
- [83] Treuer AV, Gonzalez DR. Nitric oxide synthases, S-nitrosylation and cardiovascular health: from molecular mechanisms to therapeutic opportunities (review). *Mol Med Rep* 2015; 11:1555–65.
- [84] Tang L, Wang H, Ziolo MT. Targeting NOS as a therapeutic approach for heart failure. *Pharmacol Ther* 2014;142:306–15.
- [85] Ziolo MT, Kohr MJ, Wang H. Nitric oxide signaling and the regulation of myocardial function. *J Mol Cell Cardiol* 2008;45:625–32.
- [86] Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. *Nature* 2002;416:337–9.
- [87] Sears CE, Bryant SM, Ashley EA, Lygate CA, Rakovic S, Wallis HL, et al. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. *Circ Res* 2003;92:e52–9.

- [88] Wang H, Kohr MJ, Traynham CJ, Wheeler DG, Janssen PM, Ziolo MT. Neuronal nitric oxide synthase signaling within cardiac myocytes targets phospholamban. *Am J Physiol Cell Physiol* 2008;294:C1566–75.
- [89] Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, El-Armouche A, et al. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. *Circ Res* 2008;102:242–9.
- [90] Ashley EA, Sears CE, Bryant SM, Watkins HC, Casadei B. Cardiac nitric oxide synthase 1 regulates basal and beta-adrenergic contractility in murine ventricular myocytes. *Circulation* 2002;105:3011–6.
- [91] Khan SA, Skaf MW, Harrison RW, Lee K, Minhas KM, Kumar A, et al. Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. *Circ Res* 2003;92:1322–9.
- [92] Burger DE, Lu X, Lei M, Xiang FL, Hammoud L, Jiang M, et al. Neuronal nitric oxide synthase protects against myocardial infarction-induced ventricular arrhythmia and mortality in mice. *Circulation* 2009;120:1345–54.
- [93] Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. *Circulation* 2005;112:3729–37.
- [94] Loyer X, Gomez AM, Milliez P, Fernandez-Velasco M, Vangheluwe P, Vinet L, et al. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. *Circulation* 2008;117:3187–98.
- [95] Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, et al. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. *Circulation* 2005;112:3415–22.
- [96] Jayakumari NR, Reghuvaran AC, Rajendran RS, Pillai VV, Karunakaran J, Sreelatha HV, et al. Are nitric oxide-mediated protein modifications of functional significance in diabetic heart? ye'S, -NO', wh'Y-NO't?. *Nitric Oxide* 2014;43:35–44.
- [97] Khanna S, Singh GB, Khullar M. Nitric oxide synthases and diabetic cardiomyopathy. *Nitric Oxide* 2014;43:29–34.
- [98] Pechanova O, Varga ZV, Cebova M, Giricz Z, Pacher P, Ferdinandy P. Cardiac NO signalling in the metabolic syndrome. *Br J Pharmacol* 2015;172:1415–33.

- [99] Beigi F, Gonzalez DR, Minhas KM, Sun QA, Foster MW, Khan SA, et al. Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function. *Proc Natl Acad Sci U S A* 2012;109:4314–9.
- [100] Kyrychenko S, Polakova E, Kang C, Pocsai K, Ullrich ND, Niggli E, et al. Hierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathy. *Cardiovasc Res* 2013;97:666–75.
- [101] Niggli E, Ullrich ND, Gutierrez D, Kyrychenko S, Polakova E, Shirokova N. Posttranslational modifications of cardiac ryanodine receptors: Ca(2+) signaling and EC-coupling. *Biochim Biophys Acta* 2013;1833:866–75.
- [102] Watts VL, Sepulveda FM, Cingolani OH, Ho AS, Niu X, Kim R, et al. Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation. *J Mol Cell Cardiol* 2013;62:8–17.
- [103] Burkard N, Williams T, Czolbe M, Blomer N, Panther F, Link M, et al. Conditional overexpression of neuronal nitric oxide synthase is cardioprotective in ischemia/reperfusion. *Circulation* 2010;122:1588–603.
- [104] Lai Y, Zhao J, Yue Y, Wasala NB, Duan D. Partial restoration of cardiac function with DeltaPDZ nNOS in aged mdx model of Duchenne cardiomyopathy. *Hum Mol Genet* 2014;23:3189–99.
- [105] Treuer AV, Gonzalez DR. NOS1AP modulates intracellular Ca(2+) in cardiac myocytes and is up-regulated in dystrophic cardiomyopathy. *Int J Physiol Pathophysiol Pharmacol* 2014;6:37–46.
- [106] Piantadosi CA. Regulation of mitochondrial processes by protein S-nitrosylation. *Biochim Biophys Acta* 2012;1820:712–21.
- [107] Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. *Proc Natl Acad Sci U S A* 2004;101:15944–8.
- [108] Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. *J Clin Invest* 2005;115:1221–31.
- [109] Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. *Circulation* 2008;117:2626–36.
- [110] Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, et al. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. *J Mol Cell Cardiol* 2009;47:576–85.

- [111] Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. *Circulation* 2003;108:754–9.
- [112] Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. *Circulation* 2010;121:519–28.
- [113] Carnicer R, Hale AB, Suffredini S, Liu X, Reilly S, Zhang MH, et al. Cardiomyocyte GTP cyclohydrolase 1 and tetrahydrobiopterin increase NOS1 activity and accelerate myocardial relaxation. *Circ Res* 2012;111:718–27.
- [114] Zhang YL, Wei JR. 3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model. *Mol Med Rep* 2013;8:989–94.
- [115] Song D, Kuo KH, Yao R, Hutchings SR, Pang CC. Inducible nitric oxide synthase depresses cardiac contractile function in Zucker diabetic fatty rats. *Eur J Pharmacol* 2008;579:253–9.
- [116] Frustaci A, Ciccosanti F, Chimenti C, Nardacci R, Corazzari M, Verardo R, et al. Histological and proteomic profile of diabetic versus non-diabetic dilated cardiomyopathy. *Int J Cardiol* 2016;203:282–9.
- [117] Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, Ungvari Z, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. *Am J Physiol Heart Circ Physiol* 2010;299:H985–H994.
- [118] Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. *J Nutr Biochem* 2015;26:1298–307.
- [119] Reif A, Frohlich LG, Kotsonis P, Frey A, Bommel HM, Wink DA, et al. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. *J Biol Chem* 1999;274:24921–9.
- [120] Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 2000;347 Pt 1:1–16.
- [121] Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. *J Clin Invest* 2003;112:725–35.
- [122] Gangula PR, Mukhopadhyay S, Ravella K, Cai S, Channon KM, Garfield RE, et al. Tetrahydrobiopterin (BH4), a cofactor for nNOS, restores gastric emptying and nNOS expression in female diabetic rats. *Am J Physiol Gastrointest Liver Physiol* 2010;298:G692–9.

- [123] Gangula PR, Mukhopadhyay S, Pasricha PJ, Ravella K. Sepiapterin reverses the changes in gastric nNOS dimerization and function in diabetic gastroparesis. *Neurogastroenterol Motil* 2010;22:1325–2.
- [124] Esberg LB, Ren J. Role of nitric oxide, tetrahydrobiopterin and peroxynitrite in glucose toxicity-associated contractile dysfunction in ventricular myocytes. *Diabetologia* 2003;46:1419–27.
- [125] Roe ND, He EY, Wu Z, Ren J. Folic acid reverses nitric oxide synthase uncoupling and prevents cardiac dysfunction in insulin resistance: role of Ca²⁺/calmodulin-activated protein kinase II. *Free Radic Biol Med* 2013;65:234–43.
- [126] Jo H, Otani H, Jo F, Shimazu T, Okazaki T, Yoshioka K, et al. Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice. *Clin Exp Pharmacol Physiol* 2011;38:485–93.
- [127] Baumgardt SL, Paterson M, Leucker TM, Fang J, Zhang DX, Bosnjak ZJ, et al. Chronic co-administration of sepiapterin and l-citrulline ameliorates diabetic cardiomyopathy and myocardial ischemia/reperfusion injury in obese type 2 diabetic mice. *Circ Heart Fail* 2016;9:e002424.
- [128] Moens AL, Kass DA. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. *J Cardiovasc Pharmacol* 2007;50:238–46.